Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1

Conditions

Multiple Myeloma 420Precursor Cell Lymphoblastic Leukemia-Lymphoma 126Neoplasms, Plasma Cell 74Recurrence 70Lymphoma 57Leukemia 54Neoplasms 46Immunoglobulin Light-chain Amyloidosis 38Burkitt Lymphoma 37Vomiting 36Lymphoma, Mantle-Cell 32Lymphoma, Large B-Cell, Diffuse 31Nausea 29Lymphoma, Non-Hodgkin 28Breast Neoplasms 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 21Hodgkin Disease 21Leukemia, Lymphocytic, Chronic, B-Cell 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasm Metastasis 17Prostatic Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Amyloidosis 16Leukemia, Myeloid, Acute 15Smoldering Multiple Myeloma 14Lymphoma, B-Cell, Marginal Zone 13Lung Neoplasms 11Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 10

Interventions

fludarabine phosphate 4Dexamethasone 4Peripheral Blood Stem Cell Transplantation 3Melphalan 3pomalidomide 2ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2venetoclax 1ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carmustine, poliferprosan 20 drug combination 1auricularum 1Sirolimus 1RG7388 1Nivolumab 1Maintenance 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Calcium Dobesilate 1Bortezomib 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Chromosome 17 deletion × Dexamethasone × Clear all
NCT01745640 2026-02-05

IFM2010-02

University Hospital, Lille

Phase 2 Completed
63 enrolled
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT04124497 2025-08-08

DPd

Fondazione EMN Italy Onlus

Phase 2 Active not recruiting
45 enrolled
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT04008888 2019-07-05

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Unknown
50 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡